Abstract
γ-secretase is a membrane-embedded aspartyl protease carrying out cleavage of more than 100 single transmembrane-spanning proteins, including APP, Notch, N-cadherin, etc. Its subunit, presenilin (PS) is the catalytic component, of which mutations are a major cause of early onset familial Alzheimer disease (FAD). These mutations lead to an increase in the production of the highly amyloidogenic Aβ42 isoform. Drugs aimed at γ-secretase are now considered to be promising therapeutic targets for AD. γ-secretase inhibitors (GSIs) were first introduced into clinical trials due to their efficacy in lowering Aβ production, but later were found to cause severe adverse events due to their blockage of the Notch signaling process. γ-secretase modulators (GSMs) were developed to modulate γ-secretase activity by selectively targeting Aβ42 reduction over the Notch pathway, which have been shown to have less side effects. Although clinical studies show that none of the GSIs or GSMs have been proven to be fully effective, they shed light on the physiological role of γ-secretase and PS in AD development. At the same time, natural products, due to their structural diversity and pleiotropic profile, can modulate γ-secretase activity in a dose-dependent manner, broadening our vision of drug development. With the structural information of γ-secretase released recently, we speculate there will be an explosion of γ-secretase modulators targeting not only the proteolysic center but also the interaction of its different components.
Keywords: Alzheimer disease, γ-secretase inhibitors, γ-secretase modulators, Natural products, Presenilin.
Current Topics in Medicinal Chemistry
Title:Anti-Alzheimer Therapeutic Drugs Targeting γ-Secretase
Volume: 16 Issue: 5
Author(s): Yan Tan, Qi Zhang, Steven G. Wong and Qian Hua
Affiliation:
Keywords: Alzheimer disease, γ-secretase inhibitors, γ-secretase modulators, Natural products, Presenilin.
Abstract: γ-secretase is a membrane-embedded aspartyl protease carrying out cleavage of more than 100 single transmembrane-spanning proteins, including APP, Notch, N-cadherin, etc. Its subunit, presenilin (PS) is the catalytic component, of which mutations are a major cause of early onset familial Alzheimer disease (FAD). These mutations lead to an increase in the production of the highly amyloidogenic Aβ42 isoform. Drugs aimed at γ-secretase are now considered to be promising therapeutic targets for AD. γ-secretase inhibitors (GSIs) were first introduced into clinical trials due to their efficacy in lowering Aβ production, but later were found to cause severe adverse events due to their blockage of the Notch signaling process. γ-secretase modulators (GSMs) were developed to modulate γ-secretase activity by selectively targeting Aβ42 reduction over the Notch pathway, which have been shown to have less side effects. Although clinical studies show that none of the GSIs or GSMs have been proven to be fully effective, they shed light on the physiological role of γ-secretase and PS in AD development. At the same time, natural products, due to their structural diversity and pleiotropic profile, can modulate γ-secretase activity in a dose-dependent manner, broadening our vision of drug development. With the structural information of γ-secretase released recently, we speculate there will be an explosion of γ-secretase modulators targeting not only the proteolysic center but also the interaction of its different components.
Export Options
About this article
Cite this article as:
Tan Yan, Zhang Qi, Wong G. Steven and Hua Qian, Anti-Alzheimer Therapeutic Drugs Targeting γ-Secretase, Current Topics in Medicinal Chemistry 2016; 16 (5) . https://dx.doi.org/10.2174/1568026615666150813144151
DOI https://dx.doi.org/10.2174/1568026615666150813144151 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
West Nile Viral Meningoencephalitis in an Immunocompetent Female: A Case Report from Western Rajasthan, India
Infectious Disorders - Drug Targets Concomitant Gene Mutations of MBL and CYBB in Chronic Granulomatous Disease: Implications for Host Defense
Inflammation & Allergy - Drug Targets (Discontinued) Heterogeneity in Cost-Effectiveness Analysis of Vaccination for Mild and Moderate Alzheimer’s Disease
Current Alzheimer Research Vascular Oxidative Stress and Mitochondrial Failure in the Pathobiology of Alzheimer’s Disease: A New Approach to Therapy
CNS & Neurological Disorders - Drug Targets Meningitis Due to Cryptococcus neoformans: Treatment with Posaconazole
Current HIV Research Clearance of Amyloid-β Peptide Across the Blood-Brain Barrier: Implication for Therapies in Alzheimers Disease
CNS & Neurological Disorders - Drug Targets Detection of Cryptococcus neoformans Capsular Antigen in HIV-Infected Patients in the State of Para in the North of Brazil
Current HIV Research Update on Childhood Brucellosis
Recent Patents on Anti-Infective Drug Discovery Astrocytes: Implications for Neuroinflammatory Pathogenesis of Alzheimers Disease
Current Alzheimer Research Metal and Inflammatory Targets for Alzheimers Disease
Current Drug Targets Cerebrovascular Diseases in HIV-Infected Patients
Current HIV Research New Developments of Clinical Trial in Immunotherapy for Alzheimer's Disease
Current Pharmaceutical Biotechnology Pharmacokinetics of Antifungal Agents in Neonates and Young Infants
Current Medicinal Chemistry The Amyloid β-Protein Precursor and Alzheimers Disease. Therapeutic Approaches
Current Medicinal Chemistry - Central Nervous System Agents PFGE: Importance in Food Quality
Recent Patents on Food, Nutrition & Agriculture Discovery, SAR and Medicinal Chemistry of Herpesvirus Helicase Primase Inhibitors
Current Medicinal Chemistry - Anti-Infective Agents Neurocysticercosis: The Enigmatic Disease
Central Nervous System Agents in Medicinal Chemistry The Neonatal Immune System: General Concepts and Clinical Correlations
Current Immunology Reviews (Discontinued) The Central Role of Angiotensin I-Converting Enzyme in Vertebrate Pathophysiology
Current Topics in Medicinal Chemistry Tau as a Therapeutic Target for Alzheimers Disease
Current Alzheimer Research